Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858135 | 1.00 | HPRT1 (0.62) | HPRT1PNP | |
| SCHEMBL3853984 | 1.00 | HPRT1 (0.62) | HPRT1PNP | |
| SCHEMBL15078159 | 0.89 | POLB (0.65) | HPRT1PNP | |
| SCHEMBL4715034 | 0.84 | HPRT1 (0.70) | HPRT1PNP | |
| SCHEMBL4713142 | 0.84 | HPRT1 (0.70) | HPRT1PNP | |
| SCHEMBL172846 | 0.84 | HPRT1 (0.70) | HPRT1PNP | |
| SCHEMBL8896249 | 0.83 | BLM (0.64) | HPRT1PNP | |
| SCHEMBL8895278 | 0.82 | MEN1 (0.63) | HPRT1PNP | |
| SCHEMBL6271393 | 0.82 | TK1 (0.58) | HPRT1PNP | |
| SCHEMBL3850969 | 0.82 | CYP3A4 (0.52) | HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | HPRT1 16/4885PNP 15/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | HPRT1 16/4885PNP 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.